Evolent Health (NYSE:EVH) Price Target Cut to $15.00 by Analysts at JPMorgan Chase & Co.

Evolent Health (NYSE:EVH) had its price target lowered by JPMorgan Chase & Co. from $45.00 to $15.00 in a research note released on Friday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the technology company’s stock.

Other equities analysts also recently issued reports about the company. Oppenheimer cut their price objective on Evolent Health from $34.00 to $28.00 and set an “outperform” rating on the stock in a report on Monday, November 18th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $20.00 price target on shares of Evolent Health in a research report on Tuesday, November 12th. Barclays decreased their price objective on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. JMP Securities cut their target price on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a research note on Friday, August 9th. Finally, Truist Financial reaffirmed a “buy” rating and set a $33.00 price target on shares of Evolent Health in a research report on Tuesday, August 27th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Evolent Health currently has an average rating of “Buy” and a consensus price target of $25.90.

Evolent Health Trading Down 2.9 %

EVH stock opened at $11.25 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -12.36 and a beta of 1.58. The business has a fifty day simple moving average of $23.26 and a 200-day simple moving average of $23.74. Evolent Health has a 52 week low of $11.17 and a 52 week high of $35.00.

Institutional Trading of Evolent Health

A number of hedge funds and other institutional investors have recently modified their holdings of EVH. Principal Financial Group Inc. grew its stake in Evolent Health by 3.2% during the 2nd quarter. Principal Financial Group Inc. now owns 15,594 shares of the technology company’s stock valued at $298,000 after purchasing an additional 480 shares in the last quarter. Ascent Group LLC increased its stake in shares of Evolent Health by 2.8% in the first quarter. Ascent Group LLC now owns 20,330 shares of the technology company’s stock worth $667,000 after buying an additional 550 shares during the last quarter. SeaCrest Wealth Management LLC raised its holdings in Evolent Health by 6.3% in the second quarter. SeaCrest Wealth Management LLC now owns 10,200 shares of the technology company’s stock valued at $195,000 after acquiring an additional 600 shares in the last quarter. American International Group Inc. boosted its stake in Evolent Health by 1.2% during the 1st quarter. American International Group Inc. now owns 55,402 shares of the technology company’s stock valued at $1,817,000 after acquiring an additional 640 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in Evolent Health by 2.3% during the 2nd quarter. Arizona State Retirement System now owns 29,083 shares of the technology company’s stock worth $556,000 after acquiring an additional 649 shares in the last quarter.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.